EUVIMEDEUVIMED entdecken
Crossref

Involvement of orexin nerves in early stage of Alzheimer's disease model mice and preventive effect of orexin receptor antagonists

Kazuhiro Hada iD, Yuki Murata, Yoshiaki Ohi, Sana Hashimoto, Hinata Watanabe, Kayoko Ozeki iD, Takaomi C Saido iD, Takashi Saito, Hiroki Sasaguri, Hiroyuki Mizoguchi, Kiyofumi Yamada iD, Yoshifumi Wakiya

Journal of Alzheimer’s Disease · 2026-03 · 110 (2) · 588-604

DOI: 10.1177/13872877261415630 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Alzheimer’s Disease, online erschienen am 12.03.2026. Verfasst von Kazuhiro Hada und 11 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Pharmacy Practice and Science, School of Pharmacy, Aichi Gakuin University, Nagoya, Japan. Hauptthemen laut MEDLINE: Alzheimer Disease, Orexin Receptor Antagonists, Orexin Receptors, Pyridines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 107 Literaturangaben. Gefördert von: Nitto, Institute of Pharmaceutical Life Sciences, Aichi Gakuin University, Ichihara International Scholarship Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Orexin (OX) levels are elevated in the cerebrospinal fluid of patients with mild cognitive impairment (MCI) and Alzheimer's disease (AD).

Objective

To investigate the efficacy of dual OX receptor antagonists (suvorexant and lemborexant) in an early-stage AD mouse model (App-KI).

Methods

OX receptor gene expression was measured. Additionally, drug distribution and effects on motor activity following single oral administration of suvorexant and lemborexant were assessed. Furthermore, cognitive function, amyloid-β (Aβ) levels and uptake by microglia in the hippocampal CA1 region were evaluated following daily administration of suvorexant and lemborexant for 60 days.

Results

OXR gene expression was highest in the lateral hypothalamus of wild-type mice and was also observed in other brain regions. OX1R gene expression was significantly increased in these brain regions in App-KI mice. In wild-type mice, brain concentrations of suvorexant peaked 20 to 40 min after administration, and those of lemborexant peaked 15 min after administration. Concentrations subsequently declined but remained detectable 24 h after administration. Additionally, motor activity decreased following the administration of either suvorexant or lemborexant; however, no difference in motor activity was observed compared to the control group 24 h later. Notably, the Y-maze test revealed that suvorexant and lemborexant mitigated cognitive impairment in App-KI mice. Furthermore, both drugs suppressed the accumulation of Aβ in the CA1 region of the hippocampus in App-KI mice. This was associated with increased Aβ uptake by activated microglia.

Conclusions

The results suggest that suvorexant and lemborexant effectively suppresses the early stages of AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseOrexin Receptor AntagonistsOrexin ReceptorsPyridinesAnimalsTriazolesAzepinesDisease Models, AnimalMice, TransgenicMiceAmyloid beta-PeptidesMalePyrimidinesAmyloid beta-Protein PrecursorMice, Inbred C57BLBrainMaze LearningMicroglia

Stichwörter der Autor:innen

Alzheimer's diseaseamyloid-βcognitionlemborexantmild cognitive impairmentorexinorexin receptor antagonistsuvorexant

Substanzen

Orexin Receptor AntagonistsTriazolesAzepinessuvorexantAmyloid beta-PeptidesOrexin ReceptorslemborexantPyridinesPyrimidinesAmyloid beta-Protein Precursor

Autor:innen und Institutionen

  • Laboratory of Pharmacy Practice and Science, School of Pharmacy, Aichi Gakuin University, Nagoya, Japan.
  • Department of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Laboratory of Organic and Medicinal Chemistry, School of Pharmacy, Aichi Gakuin University, Nagoya, Japan.
  • Laboratory of Neuropharmacology, School of Pharmacy, Aichi Gakuin University, Nagoya, Japan.
  • Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, Wako, Japan.
  • Department of Neurocognitive Science, Institute of Brain Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

ORCID-Profile: Kazuhiro Hada, Kayoko Ozeki, Takaomi C Saido, Kiyofumi Yamada

Förderung

  • Nitto
  • Institute of Pharmaceutical Life Sciences, Aichi Gakuin University
  • Ichihara International Scholarship Foundation
  • Grant-in-Aid for Early-Career Scientists
  • Japan Agency for Medical Research and Development
  • The Clinical Research Promotion Foundation
  • THE HORI SCIENCE AND ARTS FOUNDATION
  • THE FORDAYS FOUNDATION

Zitieren

APA

Hada, K., Murata, Y., Ohi, Y., Hashimoto, S., Watanabe, H., Ozeki, K., Saido, T. C., Saito, T., Sasaguri, H., Mizoguchi, H., Yamada, K., & Wakiya, Y. (2026). Involvement of orexin nerves in early stage of Alzheimer's disease model mice and preventive effect of orexin receptor antagonists. Journal of Alzheimer’s Disease, 110(2), 588-604. https://doi.org/10.1177/13872877261415630

Vancouver

Hada K, Murata Y, Ohi Y, Hashimoto S, Watanabe H, Ozeki K, et al. Involvement of orexin nerves in early stage of Alzheimer's disease model mice and preventive effect of orexin receptor antagonists. Journal of Alzheimer’s Disease. 2026;110(2):588-604. doi:10.1177/13872877261415630

BibTeX
@article{Hada2026,
  author = {Hada, Kazuhiro and Murata, Yuki and Ohi, Yoshiaki and Hashimoto, Sana and Watanabe, Hinata and Ozeki, Kayoko and Saido, Takaomi C and Saito, Takashi and Sasaguri, Hiroki and Mizoguchi, Hiroyuki and Yamada, Kiyofumi and Wakiya, Yoshifumi},
  title = {Involvement of orexin nerves in early stage of Alzheimer's disease model mice and preventive effect of orexin receptor antagonists},
  journal = {Journal of Alzheimer’s Disease},
  year = {2026},
  volume = {110},
  number = {2},
  pages = {588--604},
  doi = {10.1177/13872877261415630}
}
Kostenlos starten →